Q3 2024 Earnings Forecast for Teladoc Health, Inc. (NYSE:TDOC) Issued By Zacks Research

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Zacks Research reduced their Q3 2024 earnings estimates for shares of Teladoc Health in a research note issued on Tuesday, September 3rd. Zacks Research analyst D. Chatterjee now anticipates that the health services provider will earn ($0.34) per share for the quarter, down from their prior forecast of ($0.28). The consensus estimate for Teladoc Health's current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Teladoc Health's Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.31) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($1.16) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.97) EPS.

TDOC has been the topic of several other research reports. Stifel Nicolaus reduced their target price on shares of Teladoc Health from $16.00 to $9.00 and set a "hold" rating on the stock in a report on Thursday, August 1st. Bank of America dropped their price objective on shares of Teladoc Health from $16.50 to $13.50 and set a "neutral" rating on the stock in a research note on Tuesday, May 14th. Evercore ISI dropped their price target on shares of Teladoc Health from $14.00 to $10.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 9th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Teladoc Health from $15.00 to $10.00 and set a "hold" rating on the stock in a report on Friday, August 2nd. Finally, Piper Sandler lowered their target price on Teladoc Health from $25.00 to $10.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Fourteen equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $12.44.

Teladoc Health Trading Down 2.1 %

TDOC traded down $0.16 on Friday, reaching $7.51. 5,215,207 shares of the company's stock were exchanged, compared to its average volume of 5,523,281. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -5.33 and a beta of 0.90. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66. Teladoc Health has a twelve month low of $6.76 and a twelve month high of $22.98. The company's 50 day moving average is $8.25 and its 200-day moving average is $11.43.

Teladoc Health (NYSE:TDOC - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The health services provider reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.08. The company had revenue of $642.44 million during the quarter, compared to analyst estimates of $649.34 million. Teladoc Health had a negative return on equity of 10.25% and a negative net margin of 38.54%.

Insider Activity

In other news, insider Vidya Raman-Tangella sold 3,857 shares of the company's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the sale, the insider now owns 33,667 shares in the company, valued at $274,049.38. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Vidya Raman-Tangella sold 3,857 shares of the company's stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $8.14, for a total transaction of $31,395.98. Following the completion of the sale, the insider now directly owns 33,667 shares of the company's stock, valued at $274,049.38. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Laizer Kornwasser sold 10,879 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $88,555.06. Following the completion of the transaction, the chief executive officer now owns 99,929 shares of the company's stock, valued at approximately $813,422.06. The disclosure for this sale can be found here. Insiders sold 57,819 shares of company stock worth $442,204 over the last three months. Corporate insiders own 0.95% of the company's stock.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently made changes to their positions in TDOC. Granite Bay Wealth Management LLC purchased a new position in Teladoc Health during the 2nd quarter valued at about $1,111,000. Doheny Asset Management CA purchased a new stake in Teladoc Health in the 2nd quarter worth approximately $46,000. Clearline Capital LP boosted its stake in shares of Teladoc Health by 395.6% during the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider's stock valued at $42,682,000 after buying an additional 3,483,665 shares during the period. Susquehanna Fundamental Investments LLC increased its stake in shares of Teladoc Health by 32.9% in the second quarter. Susquehanna Fundamental Investments LLC now owns 265,513 shares of the health services provider's stock worth $2,597,000 after acquiring an additional 65,767 shares during the last quarter. Finally, Scientech Research LLC purchased a new stake in shares of Teladoc Health during the second quarter worth $386,000. Hedge funds and other institutional investors own 76.82% of the company's stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.